A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.

@article{Hajak2009A2E,
  title={A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.},
  author={Goeran Hajak and Jan Hedner and Mirjam Eglin and Henrik Loft and Signe ı́ St{\'o}rustovu and Simone L{\"u}tolf and Jonas Lundahl},
  journal={Sleep medicine},
  year={2009},
  volume={10 7},
  pages={705-12}
}
OBJECTIVES To evaluate the efficacy and safety profile of gaboxadol, a selective extrasynaptic GABA(A) agonist (SEGA) previously in development for the treatment of insomnia. METHODS This was a randomised, double-blind, placebo-controlled, parallel-group, 2-week, Phase III study of gaboxadol 5, 10 and 15mg in outpatients meeting the DSM-IV criteria of primary insomnia (N=742). Zolpidem 10mg was used as active reference. RESULTS At weeks 1 and 2, significant improvement in total sleep time… CONTINUE READING